CytRx: all eyes on aldoxorubicin, say analysts

3 September 2013

US biotech firm CytRx Corp (Nasdaq: CYTR) is entering a critical six-month period as aldoxorubicin delivers important clinical milestones, comment analysts at Edison Investment Research.

A positive Phase IIb readout in front-line soft tissue sarcoma (STS) in fourth-quarter 2013 could support progression into Phase III, increase confidence in the second-line opportunity (Phase III to start first-quarter 2014) and heighten partnering interest. Separately, the Phase IIb trial in glioblastoma (GBM) will start in early-fourth-quarter 2013.

Based on existing data, we are optimistic that aldoxorubicin will demonstrate efficacy (progression free survival, PFS) and/or safety advantages over doxorubicin in advanced, treatment-naïve STS patients. A positive Phase IIb readout could support progression into a pivotal Phase III study in front-line STS, increases the analysts’ confidence in the second-line opportunity, and heighten partnering interest in both aldoxorubicin and CytRx’ albumin-binding linker platform.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK